Screener
CG Oncology CGON Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 1,691 | 180 |
| Stock-based compensation expense | 20,808 | 12,158 |
| Unrealized losses (gains) on short-term investments | 4,668 | (2,166) |
| Non-cash interest expense (income) | 92 | (675) |
| Non-cash lease expense | 38 | 13 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,882) | 234 |
Item 1. Financial Statements.
FAQ
- What is CG Oncology's net gains (losses) on investments?
- CG Oncology (CGON) reported net gains (losses) on investments of -$3M in Q2 2026.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about CG Oncology's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude